The Filings Report

Roivant Sciences Ltd. Common Shares

ROIVNasdaqCIK 1635088Healthcare / Drug Manufacturersfiscal year ends March25 quarters since 2020

Revenue, Q1 FY2027
$1M
−33.5% on Q1 FY2026
Net income
−$190M
+15.0% on Q1 FY2026
Free cash flow
−$271M
−30.0% on Q1 FY2026
Diluted EPS
$-0.26
+21.2% on Q1 FY2026
Revenue, TTM
$8M
trailing four quarters
Net margin, TTM
-3535.0%
net income −$266M
Free cash flow, TTM
−$821M
−$816M less $5M capex
Cash and equivalents
$1.2B
long-term debt —, Jun 30, 2026
Shares, 12-month change
+5.8%
722M shares, Jun 30, 2026, split-adjusted
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$26.7B
at the close, buybacks

Latest quarter Q1 FY2027, filed August 6, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q1 FY2027, the quarter ended June 30, 2026, Roivant Sciences Ltd. Common Shares reported revenue of $1M, −33.5% on Q1 FY2026, and net loss of $190M (+15.0%). Operating margin was −25380.9%. Free cash flow, operating cash flow less capital expenditures, was −$271M (−$271M less $419K). Diluted earnings per share were $-0.26.

The last 16 quarters

Q2 FY2023 to Q1 FY2027, through the filing of August 6, 2026.

Revenue and net incomeRevenueNet income
−$2B$0$2B$4B$6BQ2'23, Revenue: $13MQ2'23, Net income: −$292MQ2'23Q3'23, Revenue: $17MQ3'23, Net income: −$352MQ3'23Q4'23, Revenue: −$2MQ4'23, Net income: −$34MQ4'23Q1'24, Net income: −$292MQ1'24Q2'24, Net income: −$304MQ2'24Q3'24, Net income: $5.1BQ3'24Q4'24, Net income: −$151MQ4'24Q1'25, Revenue: $8MQ1'25, Net income: $95MQ1'25Q2'25, Revenue: $4MQ2'25, Net income: −$230MQ2'25Q3'25, Revenue: $9MQ3'25, Net income: $169MQ3'25Q4'25, Revenue: $8MQ4'25, Net income: −$206MQ4'25Q1'26, Revenue: $2MQ1'26, Net income: −$223MQ1'26Q2'26, Revenue: $2MQ2'26, Net income: −$114MQ2'26Q3'26, Revenue: $2MQ3'26, Net income: −$266MQ3'26Q4'26, Revenue: $3MQ4'26, Net income: $303MQ4'26Q1'27, Revenue: $1MQ1'27, Net income: −$190MQ1'27−$2B$0$2B$4B$6BQ2'23, Revenue: $13MQ2'23, Net income: −$292MQ3'23, Revenue: $17MQ3'23, Net income: −$352MQ3'23Q4'23, Revenue: −$2MQ4'23, Net income: −$34MQ1'24, Net income: −$292MQ1'24Q2'24, Net income: −$304MQ3'24, Net income: $5.1BQ3'24Q4'24, Net income: −$151MQ1'25, Revenue: $8MQ1'25, Net income: $95MQ1'25Q2'25, Revenue: $4MQ2'25, Net income: −$230MQ3'25, Revenue: $9MQ3'25, Net income: $169MQ3'25Q4'25, Revenue: $8MQ4'25, Net income: −$206MQ1'26, Revenue: $2MQ1'26, Net income: −$223MQ1'26Q2'26, Revenue: $2MQ2'26, Net income: −$114MQ3'26, Revenue: $2MQ3'26, Net income: −$266MQ3'26Q4'26, Revenue: $3MQ4'26, Net income: $303MQ1'27, Revenue: $1MQ1'27, Net income: −$190MQ1'27

Net income losses drawn in red.

Free cash flow
−$300M−$200M−$100M$0$100MQ2'23, Free cash flow: −$193MQ2'23Q3'23, Free cash flow: −$223MQ3'23Q4'23, Free cash flow: −$181MQ4'23Q1'24, Free cash flow: −$250MQ1'24Q2'24, Free cash flow: −$197MQ2'24Q3'24, Free cash flow: −$211MQ3'24Q4'24, Free cash flow: −$109MQ4'24Q1'25, Free cash flow: −$194MQ1'25Q2'25, Free cash flow: −$268MQ2'25Q3'25, Free cash flow: −$209MQ3'25Q4'25, Free cash flow: −$173MQ4'25Q1'26, Free cash flow: −$208MQ1'26Q2'26, Free cash flow: −$194MQ2'26Q3'26, Free cash flow: −$192MQ3'26Q4'26, Free cash flow: −$165MQ4'26Q1'27, Free cash flow: −$271MQ1'27−$300M−$200M−$100M$0$100MQ2'23, Free cash flow: −$193MQ3'23, Free cash flow: −$223MQ3'23Q4'23, Free cash flow: −$181MQ1'24, Free cash flow: −$250MQ1'24Q2'24, Free cash flow: −$197MQ3'24, Free cash flow: −$211MQ3'24Q4'24, Free cash flow: −$109MQ1'25, Free cash flow: −$194MQ1'25Q2'25, Free cash flow: −$268MQ3'25, Free cash flow: −$209MQ3'25Q4'25, Free cash flow: −$173MQ1'26, Free cash flow: −$208MQ1'26Q2'26, Free cash flow: −$194MQ3'26, Free cash flow: −$192MQ3'26Q4'26, Free cash flow: −$165MQ1'27, Free cash flow: −$271MQ1'27

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6B$8BQ2'23, Cash and equivalents: $1.6BQ2'23, Long-term debt: $376MQ2'23Q3'23, Cash and equivalents: $1.5BQ3'23, Long-term debt: $375MQ3'23Q4'23, Cash and equivalents: $1.7BQ4'23, Long-term debt: $376MQ4'23Q1'24, Cash and equivalents: $1.4BQ1'24, Long-term debt: $385MQ1'24Q2'24, Cash and equivalents: $1.4BQ2'24, Long-term debt: $389MQ2'24Q3'24, Cash and equivalents: $6.7BQ3'24, Long-term debt: $403MQ3'24Q4'24, Cash and equivalents: $6.5BQ4'24, Long-term debt: $431MQ4'24Q1'25, Cash and equivalents: $5.7BQ1'25, Long-term debt: $312MQ1'25Q2'25, Cash and equivalents: $2.0BQ2'25Q3'25, Cash and equivalents: $2.0BQ3'25Q4'25, Cash and equivalents: $2.7BQ4'25Q1'26, Cash and equivalents: $1.2BQ1'26Q2'26, Cash and equivalents: $1.2BQ2'26Q3'26, Cash and equivalents: $1.5BQ3'26Q4'26, Cash and equivalents: $1.4BQ4'26Q1'27, Cash and equivalents: $1.2BQ1'27$0$2B$4B$6B$8BQ2'23, Cash and equivalents: $1.6BQ2'23, Long-term debt: $376MQ3'23, Cash and equivalents: $1.5BQ3'23, Long-term debt: $375MQ3'23Q4'23, Cash and equivalents: $1.7BQ4'23, Long-term debt: $376MQ1'24, Cash and equivalents: $1.4BQ1'24, Long-term debt: $385MQ1'24Q2'24, Cash and equivalents: $1.4BQ2'24, Long-term debt: $389MQ3'24, Cash and equivalents: $6.7BQ3'24, Long-term debt: $403MQ3'24Q4'24, Cash and equivalents: $6.5BQ4'24, Long-term debt: $431MQ1'25, Cash and equivalents: $5.7BQ1'25, Long-term debt: $312MQ1'25Q2'25, Cash and equivalents: $2.0BQ3'25, Cash and equivalents: $2.0BQ3'25Q4'25, Cash and equivalents: $2.7BQ1'26, Cash and equivalents: $1.2BQ1'26Q2'26, Cash and equivalents: $1.2BQ3'26, Cash and equivalents: $1.5BQ3'26Q4'26, Cash and equivalents: $1.4BQ1'27, Cash and equivalents: $1.2BQ1'27

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q1 FY2027 filed August 6, 2026.

Roivant Sciences Ltd. Common Shares income statement, quarterly
Millions of dollarsQ1 FY2027ended Jun 30, 2026filed Aug 6, 2026Q4 FY2026ended Mar 31, 2026filed May 20, 2026Q3 FY2026ended Dec 31, 2025filed Feb 6, 2026Q2 FY2026ended Sep 30, 2025filed Nov 10, 2025Q1 FY2026ended Jun 30, 2025filed Aug 11, 2025Q4 FY2025ended Mar 31, 2025filed May 29, 2025Q3 FY2025ended Dec 31, 2024filed Feb 10, 2025Q2 FY2025ended Sep 30, 2024filed Nov 12, 2024YoYQ1 FY2027vs Q1 FY2026
Revenue13222894−33.5%
Cost of revenue—————————
Gross profit—————————
Research and development202199165165153145142143+32.1%
Selling, general and administrative166158175143134147142203+23.5%
Operating income(366)415(339)(306)(285)(285)(274)(342)−28.5%
Other income (expense)(2)138(6)(11)(3)(3)(1)+81.0%
Pretax income(295)454(290)(159)—(203)(235)(224)—
Income tax(4)98237549(26)12−185.1%
Net income(190)303(266)(114)(223)(206)169(230)+15.0%
Diluted EPS ($)(0.26)—(0.38)(0.17)(0.33)—0.23(0.31)+21.2%
Diluted shares (millions)721—697681680—723735—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q1 FY2027 filed August 6, 2026.

Roivant Sciences Ltd. Common Shares balance sheet, quarterly
Millions of dollarsQ1 FY2027ended Jun 30, 2026filed Aug 6, 2026Q4 FY2026ended Mar 31, 2026filed May 20, 2026Q3 FY2026ended Dec 31, 2025filed Feb 6, 2026Q2 FY2026ended Sep 30, 2025filed Nov 10, 2025Q1 FY2026ended Jun 30, 2025filed Aug 11, 2025Q4 FY2025ended Mar 31, 2025filed May 29, 2025Q3 FY2025ended Dec 31, 2024filed Feb 10, 2025Q2 FY2025ended Sep 30, 2024filed Nov 12, 2024YoYQ1 FY2027vs Q1 FY2026
Cash and equivalents1,2481,4191,4781,2371,2382,7151,9911,959+0.8%
Short-term investments2,5942,8733,0523,1493,2652,1713,1563,428−20.6%
Total current assets4,7425,1674,6604,5124,6165,0005,3645,801+2.7%
Total assets5,3065,7095,2255,0635,0335,4375,7926,206+5.4%
Total current liabilities284281152134114149141556+149.1%
Long-term debt—————————
Total liabilities385416251257217250256626+77.5%
Stockholders’ equity4,2314,5274,2694,3624,3464,6885,1895,153−2.6%
Shares outstanding (millions)722719716695683680714728—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q1 FY2027 filed August 6, 2026.

Roivant Sciences Ltd. Common Shares cash flow statement, quarterly
Millions of dollarsQ1 FY2027ended Jun 30, 2026filed Aug 6, 2026Q4 FY2026ended Mar 31, 2026filed May 20, 2026Q3 FY2026ended Dec 31, 2025filed Feb 6, 2026Q2 FY2026ended Sep 30, 2025filed Nov 10, 2025Q1 FY2026ended Jun 30, 2025filed Aug 11, 2025Q4 FY2025ended Mar 31, 2025filed May 29, 2025Q3 FY2025ended Dec 31, 2024filed Feb 10, 2025Q2 FY2025ended Sep 30, 2024filed Nov 12, 2024YoYQ1 FY2027vs Q1 FY2026
Operating cash flow(271)(164)(196)(186)(204)(173)(207)(267)−32.4%
Capital expenditures01(5)84121−89.6%
Free cash flow (CFO − capex)(271)(165)(192)(194)(208)(173)(209)(268)−30.0%
Depreciation and amortization11111135−45.4%
Share repurchases207—00208295243106−0.8%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2026 filed May 20, 2026.

Income statement

Roivant Sciences Ltd. Common Shares income statement, annual
Millions of dollarsFY2026ended Mar 31, 2026filed May 20, 2026FY2025ended Mar 31, 2025filed May 29, 2025FY2024ended Mar 31, 2024filed May 30, 2024FY2023ended Mar 31, 2023filed Jun 28, 2023FY2022ended Mar 31, 2022filed Jun 28, 2022FY2021ended Mar 31, 2021filed Sep 21, 2021
Revenue82933325524
Cost of revenue——————
Gross profit——————
Research and development682550440454483237
Selling, general and administrative610591416383775260
Operating income(515)(1,003)4,497(907)(1,352)(1,071)
Other income (expense)4(11)(14)03(9)
Pretax income(265)(682)4,568(885)(924)(899)
Income tax1334822402
Net income(300)(172)4,349(1,009)(845)(809)
Diluted EPS ($)(0.54)(0.24)5.23(1.42)(1.26)—
Diluted shares (millions)694725831713670—

Balance sheet

Roivant Sciences Ltd. Common Shares balance sheet, annual
Millions of dollarsFY2026ended Mar 31, 2026filed May 20, 2026FY2025ended Mar 31, 2025filed May 29, 2025FY2024ended Mar 31, 2024filed May 30, 2024FY2023ended Mar 31, 2023filed Jun 28, 2023FY2022ended Mar 31, 2022filed Jun 28, 2022FY2021ended Mar 31, 2021filed Sep 21, 2021
Cash and equivalents1,4192,7156,4951,6772,0602,055
Short-term investments2,8732,1710———
Total current assets5,1675,0006,7321,7992,1472,187
Total assets5,7095,4377,2222,3902,5852,590
Total current liabilities281149267272184219
Long-term debt——431376210170
Total liabilities416250774782524528
Stockholders’ equity4,5274,6885,9691,1581,6571,798
Shares outstanding (millions)719680739767701—

Cash flow statement

Roivant Sciences Ltd. Common Shares cash flow statement, annual
Millions of dollarsFY2026ended Mar 31, 2026filed May 20, 2026FY2025ended Mar 31, 2025filed May 29, 2025FY2024ended Mar 31, 2024filed May 30, 2024FY2023ended Mar 31, 2023filed Jun 28, 2023FY2022ended Mar 31, 2022filed Jun 28, 2022FY2021ended Mar 31, 2021filed Sep 21, 2021
Operating cash flow(750)(839)(765)(843)(678)(552)
Capital expenditures85113176
Free cash flow (CFO − capex)(759)(844)(767)(856)(695)(558)
Depreciation and amortization31422196—
Share repurchases—1,29300——
Dividends paid——————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$67M
20 sales by 4 insiders; officers and directors $67M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$892M
117 sales by 12 insiders; officers and directors $639M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 28, 2026Venker EricPresident & Immunovant CEOopen-market sale10b5-1200,000$36.59$7M1MOct 30, 2026
Oct 23, 2026Oren IlanDirectoraward810$0.00—124,490Oct 27, 2026
Oct 23, 2026Epperly Melissa B,Directoraward513$0.00—15,467Oct 27, 2026
Oct 23, 2026Epperly Melissa B,Directortax withholding116$36.49$4K15,351Oct 27, 2026
Oct 23, 2026Momtazee James CDirectoraward383$0.00—112,342Oct 27, 2026
Oct 23, 2026Momtazee James CDirectortax withholding77$36.49$3K112,265Oct 27, 2026
Oct 20, 2026Venker EricPresident & Immunovant CEOopen-market sale10b5-1185,856$35.09$7M1MOct 22, 2026
Oct 20, 2026Venker EricPresident & Immunovant CEOopen-market sale10b5-114,144$35.42$501K1MOct 22, 2026
Oct 16, 2026Sukhatme MayukhPresident & CIO, Directortax withholding19,976$33.53$670K19MOct 20, 2026
Oct 16, 2026Gline MatthewCEO, Directortax withholding34,638$33.53$1M17MOct 20, 2026
Oct 1, 2026Roivant Sciences Ltd.Director, 10% ownerdisposition to issuer9M$5.00$45M30MOct 5, 2026
Oct 1, 2026Epperly Melissa B,Directoroption exercise17,750$4.46$79K32,704Oct 5, 2026
Oct 1, 2026Epperly Melissa B,Directoropen-market sale10b5-116,850$36.08$608K15,854Oct 5, 2026
Oct 1, 2026Epperly Melissa B,Directoropen-market sale10b5-1900$36.57$33K14,954Oct 5, 2026
Sep 30, 2026Gline MatthewCEO, Directortax withholding76,171$36.57$3M17MOct 2, 2026
Sep 30, 2026Torti FrankPresident and Vant Chairtax withholding40,309$36.57$1M13MOct 2, 2026
Sep 30, 2026Sukhatme MayukhPresident & CIO, Directortax withholding46,879$36.57$2M19MOct 2, 2026
Sep 30, 2026Venker EricPresident & Immunovant CEOoption exercise200,000$3.85$770K2MOct 2, 2026
Sep 30, 2026Venker EricPresident & Immunovant CEOopen-market sale10b5-1200,000$36.62$7M2MOct 2, 2026
Sep 20, 2026Humes JenniferChief Accounting Officertax withholding3,880$39.77$154K106,419Sep 22, 2026
Sep 20, 2026Pulik RichardCFOtax withholding2,129$39.77$85K269,681Sep 22, 2026
Sep 16, 2026Manchester Keith SDirectoraward5,054$0.00—2MSep 18, 2026
Sep 16, 2026Gold Daniel AllenDirectoraward5,054$0.00—9MSep 18, 2026
Sep 16, 2026Oren IlanDirectoraward5,054$0.00—123,680Sep 18, 2026
Sep 16, 2026Momtazee James CDirectoraward5,054$0.00—111,959Sep 18, 2026

Full insider history for Roivant Sciences Ltd. Common Shares, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 3; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
ROIVANT SCIENCES LTD., CIK 1635088 on EDGAR
Extract generated
November 1, 2026
Withheld
6 line-years whose four quarters do not sum to the filed year: operating income FY2024, opex sga FY2024, other income FY2024, pretax income FY2024, revenue FY2024, rnd FY2024
Repaired
4 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2022, income tax FY2023, income tax FY2024, pretax income FY2026
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/ROIV.json